Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

2.

Development of the computer-adaptive version of the Late-Life Function and Disability Instrument.

McDonough CM, Tian F, Ni P, Kopits IM, Moed R, Pardasaney PK, Jette AM.

J Gerontol A Biol Sci Med Sci. 2012 Dec;67(12):1427-38. doi: 10.1093/gerona/gls108. Epub 2012 Apr 30.

3.

Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility.

Kopits IM, Chen C, Roberts JS, Uhlmann W, Green RC.

Genet Test Mol Biomarkers. 2011 Dec;15(12):871-5. doi: 10.1089/gtmb.2011.0028. Epub 2011 Jul 12.

4.

New endeavors and innovative programs in end of life care.

Wilkinson AM, Harrold JK, Kopits I, Ayers E.

Hosp J. 1998;13(1-2):165-80. Review.

PMID:
9644401
5.

Observations on 750 geropsychiatric patients.

Kopits I.

J Am Geriatr Soc. 1970 May;18(5):353-64. No abstract available.

PMID:
4245199
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk